Charles River Laboratories (CRL)
Health Care · Contract Research and Manufacturing (Non-Clinical Drug Development)
A global contract research organization providing non-clinical drug development services, research models, and manufacturing solutions across discovery, safety assessment, and biologics testing.
What Charles River Laboratories does
Charles River Laboratories is a full-service, non-clinical global drug development partner with over 75 years of history in providing research models and services to support pharmaceutical, biotechnology, and other life sciences companies through the non-clinical development phase. The company operates three main segments: Research Models and Services (RMS), which supplies laboratory animals and related colony management and diagnostic services; Discovery and Safety Assessment (DSA), which provides in vitro and in vivo testing, bioanalytical services, and non-clinical consulting; and Manufacturing Solutions, which offers microbial detection products, lot-release testing, and specialized biologics testing and contract development and manufacturing (CDMO) services. These integrated offerings enable clients to improve efficiency, reduce costs, and accelerate time to market for new drugs, devices, and therapies.
Themes: ["Drug discovery outsourcing","Non-clinical safety testing","Contract research and manufacturing (CDMO)","Biologics testing and development","Laboratory animal models and services","Preclinical development support"]
Fundamentals
- Price$233.60 as of 2026-07-09 close
- Market cap$11.1B as of 2026-07-10
- 1-year return+41.4% as of 2026-07-09 close
- Net margin-4.6% as of 2026-07-10
- Gross margin+34.5% as of 2026-07-10
- ROE-5.7% as of 2026-07-10
- Debt / equity0.91 as of 2026-07-10
- Revenue growth (YoY)+0.1% as of 2026-07-10
- Revenue CAGR (3y)+0.3% SEC XBRL
- Beta1.38 as of 2026-07-10
Key risks (from latest filing)
["Cautious spending environment and weak demand in Discovery and Safety Assessment segment, with clients reducing outsourcing and delaying studies in challenging macroeconomic conditions","Non-human primate supply chain constraints and regulatory exposure related to purpose-bred primate sourcing, including pending securities and derivative lawsuits from May 2023, November 2023, and August 2024","Significant ongoing restructuring and cost-cutting initiatives required to maintain profitability, with company currently unprofitable (negative 4.59% net margin) despite targeting $300 million in annualized cost savings by end of 2026"]
Competitors & peers
- Envigo (now part of Inotiv)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.